Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Highly pathogenic avian influenza is having a deadly effect on Michigan’s eagle population. A 2022 outbreak reduced breeding ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

A rare cell in the lining of lungs is fundamental to the organ-wide response necessary to repair damage from toxins like ...

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.